Capricor Therapeutics Inc. (CAPR) and FibroGen Inc. (NASDAQ:FGEN) Comparison side by side

Capricor Therapeutics Inc. (NASDAQ:CAPR) and FibroGen Inc. (NASDAQ:FGEN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Capricor Therapeutics Inc. 1.50M 7.92 14.04M -0.52 0.00
FibroGen Inc. 204.90M 17.12 90.44M -1.04 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Capricor Therapeutics Inc. and FibroGen Inc.

Profitability

Table 2 shows us Capricor Therapeutics Inc. and FibroGen Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Capricor Therapeutics Inc. -936.00% -191.3% -118.7%
FibroGen Inc. -44.14% -28.6% -16.3%

Risk & Volatility

Capricor Therapeutics Inc.’s volatility measures that it’s 54.00% more volatile than S&P 500 due to its 1.54 beta. Competitively, FibroGen Inc. is 59.00% more volatile than S&P 500, because of the 1.59 beta.

Liquidity

6.7 and 6.7 are the respective Current Ratio and a Quick Ratio of Capricor Therapeutics Inc. Its rival FibroGen Inc.’s Current and Quick Ratios are 7.8 and 7.8 respectively. FibroGen Inc. has a better chance of clearing its pay short and long-term debts than Capricor Therapeutics Inc.

Analyst Recommendations

Capricor Therapeutics Inc. and FibroGen Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Capricor Therapeutics Inc. 0 0 1 3.00
FibroGen Inc. 0 1 4 2.80

$3.5 is Capricor Therapeutics Inc.’s average target price while its potential upside is 2.04%. Competitively the average target price of FibroGen Inc. is $71.2, which is potential 75.02% upside. The data from earlier shows that analysts view suggest that FibroGen Inc. seems more appealing than Capricor Therapeutics Inc.

Insider & Institutional Ownership

The shares of both Capricor Therapeutics Inc. and FibroGen Inc. are owned by institutional investors at 5% and 67.1% respectively. Insiders owned roughly 32.93% of Capricor Therapeutics Inc.’s shares. Comparatively, 3.7% are FibroGen Inc.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Capricor Therapeutics Inc. -8.52% -30.63% -9.37% -60.34% -70.32% -5.17%
FibroGen Inc. -18.47% -22.4% -34.26% -10.03% -23.86% -18.24%

For the past year Capricor Therapeutics Inc. has stronger performance than FibroGen Inc.

Summary

FibroGen Inc. beats Capricor Therapeutics Inc. on 8 of the 12 factors.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.